Fig. 3: Isoform-specific TGFβ inhibition is effective at delaying B16 tumor growth.
From: Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
a Therapy regimen beginning 11 days post tumor implantation with 250,000 B16 cells. Mice were treated with 8 doses of anti-TGFβ therapy given every other day via intraperitoneal injection at 200 µg/mouse (n = 10 mice/group). b Individual tumor growth curves for control and treated groups in B16 melanoma. Data are representative of three independent experiments. c Tumor size (measured as surface area in mm2) of untreated animals and animals treated with anti-TGFβ1, anti-TGFβ3, and 1D11 (pan-TGFβ inhibition) in B16 melanoma (left) (d) and CT26 colon tumors (right). Data is displayed as ± standard error the mean (SEM). Statistics were calculated using 2-way ANOVA 24 days post tumor implantation for B16 and 23 days post tumor implantation for CT26. Only statistically significant differences among untreated and treated groups are shown. *p < 0.05; ***p < 0.0005; ****p < 0.0001.
